Phase 2
N=71
SMART Trial: Intrapersonal and Interpersonal Stigma Reduction
Stigma, Social · Opioid Use · Opioid-use Disorder · Substance Use Disorders
Bottom Line
View on ClinicalTrials.gov: NCT04693416 ↗Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcome: Primary: Enacted Stigma (Intrapersonal) — 0.730 score on a scale — p=0.252
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Intrapersonal Stigma Reduction (Other); Interpersonal Stigma Reduction (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Tennessee
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Enacted Stigma (Intrapersonal) |
0.730 | 0.252 |
| PRIMARY Anticipated Stigma (Intrapersonal) |
0.514 | 0.546 |
| PRIMARY Internalized Stigma (Intrapersonal) |
2.324 | 0.005 sig |
| PRIMARY Exposure to Drug Users Index Score |
-0.476 | 0.188 |
| PRIMARY Drug Use Stigmatization Scale Score |
2.105 | 0.049 sig |
| PRIMARY Stigma of Drug Users Scale Score |
1.211 | 0.036 sig |
| SECONDARY Engagement in Treatment |
4 | — |
Summary
The goal of this project is to develop a multicomponent stigma reduction intervention to address intrapersonal (individual) stigma regarding Opioid Use Disorder (OUD). The intervention will address this cost/benefit evaluation among individuals known to face intersecting stigma of OUD and African American race, with treatment elements chosen explicitly to increase the value of treatment using salient forms of reward, and to ease perceived costs through explicit services in an effort to encourage the occurrence of the first treatment visit for OUD.
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Identify as African American, Black, or mixed race
- Identify as someone with a substance use disorder who is not currently in treatment OR a support person of someone enrolled
- Access to a telephone for follow-up assessment
- Reside in the Memphis, TN area
Exclusion Criteria
- Unable to understand consent procedures
Data sourced from ClinicalTrials.gov (NCT04693416). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.